Table 1 Baseline patient characteristics
Characteristic | No. | Percent |
|---|---|---|
Age, years | 56.6 (24-91) | |
<40 | 20 | 7.2 |
40-49 | 64 | 23.2 |
50-70 | 155 | 56.2 |
>70 | 37 | 13.4 |
Menstrual status | ||
Peri/pre-menopause | 89 | 32.2 |
Post-menopause | 187 | 67.8 |
Breast surgery type | ||
Mastectomy (+/−reconstruction) | 239 | 86.6 |
Lumpectomy | 37 | 13.4 |
Pathological type | ||
Invasive ductal carcinoma | 246 | 89.1 |
Invasive lobular carcinoma | 12 | 4.3 |
Others | 18 | 6.5 |
Tumor size | ||
Tx | 5 | 1.8 |
≤2 cm | 118 | 42.8 |
2-5 cm | 147 | 53.3 |
>5 cm | 6 | 2.2 |
Axillary lymph node | ||
Negative | 155 | 56.2 |
Positive | 121 | 43.8 |
Histologic grading | ||
I | 6 | 2.2 |
II | 134 | 48.6 |
III | 90 | 32.6 |
NA | 46 | 16.7 |
Estrogen Receptor | ||
Negative | 62 | 22.5 |
Positive | 214 | 77.5 |
Progesterone Receptor | ||
Negative | 113 | 40.9 |
Positive | 163 | 59.1 |
Hormonal Receptor | ||
Negative | 61 | 22.1 |
Positive | 215 | 77.9 |
HER2 | ||
Negative | 217 | 78.6 |
Positive | 59 | 21.4 |
Ki67 (%, mean) | 26.2 (1-90) | |
<20 | 129 | 46.7 |
≥20 | 147 | 53.3 |
Molecular subtype | ||
Luminal A | 73 | 26.4 |
Luminal B-HER2- | 109 | 39.5 |
Luminal B-HER2+ | 33 | 12.0 |
Triple negative | 35 | 12.7 |
HER2 positive | 26 | 9.4 |
Surgery time interval (days) | 4.5 (1-37) | |
1-2 | 55 | 19.9 |
3-4 | 113 | 40.9 |
≥5 | 108 | 39.1 |